TY - JOUR
T1 - Clinical significance of macroscopic T-wave alternans after sodium channel blocker administration in patients with Brugada syndrome
AU - Tada, Takeshi
AU - Kusano, Kengo Fukushima
AU - Nagase, Satoshi
AU - Banba, Kimikazu
AU - Miura, Daiji
AU - Nishii, Nobuhiro
AU - Watanabe, Atsuyuki
AU - Nakamura, Kazufumi
AU - Morita, Hiroshi
AU - Ohe, Tohru
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2008/1
Y1 - 2008/1
N2 - Clinical Significance of Macroscopic T-Wave Alternans. Introduction: Macroscopic T-wave alternans (TWA) is sometimes observed after sodium channel blocker administration in patients with Brugada syndrome (BS), but little is known about the association between occurrence of TWA and clinical characteristics in BS patients. We investigated the association between spontaneous ventricular fibrillation (VF) occurrence and TWA after pilsicainide, a sodium channel blocker administration in BS patients. Methods and Results: We administered pilsicainide at a dose of 1 mg/kg to 77 BS patients (76 males and one female; mean age, 48.4 years) and examined the association between TWA after pilsicainide administration and clinical characteristics, including age, spontaneous VF, syncope, family history of sudden death, spontaneous coved ST elevation, late potentials (LP), induction of VF by programmed electrical stimulation, and SCN5A mutation. None of the patients had TWA before pilsicainide administration, but TWA became apparent in 17 (22.1%) of the patients after pilsicainide administration. Patients with TWA had a significantly higher incidence of spontaneous VF (52.9% vs 8.3%, P < 0.001) and syncope (58.8% vs 26.7%, P < 0.05) than did patients without TWA. Then, we focused on the association between spontaneous VF and clinical characteristics. Patients with spontaneous VF had a significantly higher incidence of TWA (64.3% vs 12.7%, P < 0.001) and LP positive (92.9% vs 56.5%, P < 0.01) than did patients without spontaneous VF. In multivariate analysis, TWA (P = 0.001) and LP (P = 0.047) appeared as the independent predictor for spontaneous VF. Conclusion: TWA after pilsicainide administration is associated with a high risk of clinical VF in patients with BS.
AB - Clinical Significance of Macroscopic T-Wave Alternans. Introduction: Macroscopic T-wave alternans (TWA) is sometimes observed after sodium channel blocker administration in patients with Brugada syndrome (BS), but little is known about the association between occurrence of TWA and clinical characteristics in BS patients. We investigated the association between spontaneous ventricular fibrillation (VF) occurrence and TWA after pilsicainide, a sodium channel blocker administration in BS patients. Methods and Results: We administered pilsicainide at a dose of 1 mg/kg to 77 BS patients (76 males and one female; mean age, 48.4 years) and examined the association between TWA after pilsicainide administration and clinical characteristics, including age, spontaneous VF, syncope, family history of sudden death, spontaneous coved ST elevation, late potentials (LP), induction of VF by programmed electrical stimulation, and SCN5A mutation. None of the patients had TWA before pilsicainide administration, but TWA became apparent in 17 (22.1%) of the patients after pilsicainide administration. Patients with TWA had a significantly higher incidence of spontaneous VF (52.9% vs 8.3%, P < 0.001) and syncope (58.8% vs 26.7%, P < 0.05) than did patients without TWA. Then, we focused on the association between spontaneous VF and clinical characteristics. Patients with spontaneous VF had a significantly higher incidence of TWA (64.3% vs 12.7%, P < 0.001) and LP positive (92.9% vs 56.5%, P < 0.01) than did patients without spontaneous VF. In multivariate analysis, TWA (P = 0.001) and LP (P = 0.047) appeared as the independent predictor for spontaneous VF. Conclusion: TWA after pilsicainide administration is associated with a high risk of clinical VF in patients with BS.
KW - Brugada syndrome
KW - Macroscopic T-wave alternans
KW - Pilsicainide
KW - Ventricular fibrillation
UR - http://www.scopus.com/inward/record.url?scp=37549027631&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=37549027631&partnerID=8YFLogxK
U2 - 10.1111/j.1540-8167.2007.00967.x
DO - 10.1111/j.1540-8167.2007.00967.x
M3 - Article
C2 - 17916151
AN - SCOPUS:37549027631
SN - 1045-3873
VL - 19
SP - 56
EP - 61
JO - Journal of Cardiovascular Electrophysiology
JF - Journal of Cardiovascular Electrophysiology
IS - 1
ER -